Abstract
N-chlorotaurine (NCT), the main representative of long-lived oxidants produced by granulocytes and monocytes, is known to exert broad-spectrum microbicidal activity. Here we show that NCT directly inactivates Shiga toxin 2 (Stx2), used as a model toxin secreted by enterohemorrhagic Escherichia coli (EHEC). Bacterial growth and Stx2 production were both inhibited by 2 mM NCT. The cytotoxic effect of Stx2 on Vero cells was removed by ≥5.5 mM NCT. Confocal microscopy and FACS analyses showed that the binding of Stx2 to human kidney glomerular endothelial cells was inhibited, and no NCT-treated Stx2 entered the cytosol. Mass spectrometry displayed oxidation of thio groups and aromatic amino acids of Stx2 by NCT. Therefore, long-lived oxidants may act as powerful tools of innate immunity against soluble virulence factors of pathogens. Moreover, inactivation of virulence factors may contribute to therapeutic success of NCT and novel analogs, which are in development as topical antiinfectives.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Cell Death / drug effects
-
Chlorocebus aethiops
-
Electrophoresis, Polyacrylamide Gel
-
Endothelial Cells / cytology
-
Endothelial Cells / drug effects
-
Endothelial Cells / metabolism
-
Endothelial Cells / microbiology
-
Enterohemorrhagic Escherichia coli / drug effects
-
Enterohemorrhagic Escherichia coli / growth & development
-
Enterohemorrhagic Escherichia coli / metabolism*
-
Flow Cytometry
-
Humans
-
Kidney Glomerulus / cytology
-
Leukocytes / drug effects
-
Leukocytes / metabolism*
-
Mass Spectrometry
-
Models, Biological
-
Molecular Sequence Data
-
Oxidants / pharmacology*
-
Oxidation-Reduction / drug effects
-
Protein Binding / drug effects
-
Shiga Toxin 2 / biosynthesis
-
Shiga Toxin 2 / chemistry
-
Shiga Toxin 2 / metabolism*
-
Taurine / analogs & derivatives*
-
Taurine / pharmacology
-
Vero Cells
Substances
-
N-monochloro-2,2-dimethyltaurine
-
Oxidants
-
Shiga Toxin 2
-
Taurine
-
N-chlorotaurine
-
NVC-422
Grants and funding
This study was supported by NovaBay Pharmaceuticals, Inc., Emeryville, California, United States of America. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.